Multifaceted Strategies for Hypertension Control in Low-Income Patients. Mills KT, et al.N Engl J Med. 2026 Apr 9;394(14):1376-1387 Lire
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Azizi M, et al; Bax24 investigators. Lancet. 2026 Mar 7;407(10532):988-999 Lire
Etudes observationnelles
Impact of a Smartwatch Hypertension Notification Feature for Population Screening. Cohen JB, et al. JAMA. 2026 Mar 17;335(11):1001-1003 Lire
Revues
Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis. Bidel Z, et al; Blood Pressure Lowering Treatment Trialists’ Collaboration Eur Heart J. 2026 Apr 7;47(14):1649-1657 Lire
New drug therapies for hypertension. Azizi M, et al. Lancet. 2026 Mar 7;407(10532):1014-1028 Lire
Practical approach to evaluate and manage hypertension in youth: an International Society of Hypertension position paper. Flynn JT, et al. J Hypertens. 2026 Apr 1;44(4):553-571 Lire
Articles
Article sur la Dépêche Vétérinaire : Santé cardiovasculaire des femmes au travail : mieux prévenir et mieux dépister Lire
Article sur la Semaine Vétérinaire : Appel aux consoeurs à prendre soin de leur Coeur Lire
Pharmacogenomics-guided personalized therapy for hypertension: a multicenter randomized trial.Yu M, et al.J Hypertens. 2026 Feb 16 Lire
Adherence to Different Dietary Patterns and Subsequent Risk of Total, Ischemic, and Hemorrhagic Stroke.Castro-Barquero S, et al.Stroke. 2026 Feb 23 Lire
mHealth Intervention to Improve Hypertension Care in High-Risk Patients. Lakshminarayan K, et al.Hypertension. 2026 Feb 20 Lire
Revues
Blood-Pressure Targets in Hypertension Management. Kotanidis CP, et al.N Engl J Med. 2026 Mar 5;394(10):1026-1029 Lire
New drug therapies for hypertension. Azizi M, et al. Lancet. 2026 Feb 10 Lire
Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines. Owei L, et al. Hypertension. 2026 Feb 6 Lire
Practical approach to evaluate and manage hypertension in youth: an International Society of Hypertension position paper. Flynn JT, et al. J Hypertens. 2026 Apr 1;44(4):553-571 Lire
Forecasting the Burden of Cardiovascular Disease and Stroke in Women in the United States Through 2050: A Scientific Statement From the American Heart Association. Joynt Maddox KE, et al. Circulation. 2026 Feb 25 Lire
Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association. King JB, et al. Hypertension. 2026 Mar;83(3):e00258 Lire
Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association. Cohen JB, et al. Hypertension. 2026 Mar;83(3):e00254 Lire
Cohortes
Big Data Approach to Assessment of an Aldosterone-Renin Ratio for Detection of Potential Surgical Cases of Primary Aldosteronism.Leung AA, ey al. Hypertension. 2026 Mar 4 Lire
Association Between 24-Hour Systolic Blood Pressure Time in Target Range and Mortality. Lauder L, et al. Hypertension. 2026 Feb 27 Lire
From French Gastronomy to Cardiovascular Health: Cutting Salt in the Baguette Has Saved Thousands of Lives in France. Grave C, et al. Hypertension. 2026 Mar;83(3):e25977 Lire
Facteurs environnementaux et Hypertension artérielle Lire
PRISE EN CHARGE des facteurs de risque cardiovasculaire des personnes âgées de 75 ans et plus Lire
COMMUNIQUÉ DE LA SFHTA : Clarifications sur la terminologie et le rôle des Infirmiers en Pratique Avancée dans la prise en charge de l’Hypertension Artérielle suite au décret du 25 avril 2025. Lire
Article AMELI : Hypertension artérielle : confirmation du diagnostic et suivi par automesure tensionnelle Lire
Recommandation de remplacement ANSM : Tensions d’approvisionnement en propranolol 40 mg : l’ANSM demande de limiter les initiations de traitement Lire
Sélection d’articles
Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.Rossignol P, et al. Hypertension. 2026;83(2):e25563 Lire
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial White WB et al. J Am Coll Cardiol. 2026 Jan 13 Lire
From French Gastronomy to Cardiovascular Health: Cutting Salt in the Baguette Has Saved Thousands of Lives in France Grave C et al. Hypertension. 2026 Jan 26 Lire
Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults Wang N et al. Am J Hypertens. 2026 Jan 25:hpag003 Lire
Association of Clinic Blood Pressure and Out-of-Clinic Blood Pressure Difference With Falls Among Older Adults With Hypertension Shimbo D et al. Hypertension. 2026 Jan 22 Lire
Blood Pressure Levels and Outcomes in Type 2 Diabetes: Dose-Response Meta- Analysis of 5.87 Million Cohort Participants Wang S et al. J Am Coll Cardiol. 2026 Jan 14 Lire
Systolic inter-arm blood pressure difference and subclinical atherosclerosis: a population-based cohort study of 29 921 individuals Gottsäter A et al. J Hypertens.2026 Feb 1;44(2):346-353 Lire
Nocturnal Hypertension and Prognosis in Patients of Very Advanced Age Fujiwara T et al. Hypertension. 2026 Jan 22 Lire
Childhood Blood Pressure Predicts Longitudinal Decline in Vascular Function: The ExAMIN Youth SA Study Volschenk C et al. Hypertension. 2026;83(2):e25888 Lire
Setting the UK research priorities for hypertension using a modified Delphi approach: a British and Irish Hypertension Society Initiative with Support from the British Heart Foundation Clinical Research Collaborative Swift PA et al. J Hypertens. 2026 Mar 1;44(3):454-460 Lire
Value of Multiomics Over Clinical Risk Factors in Hypertension Prediction Vuori M et al. Hypertension. 2026 Feb;83(2):e25358 Lire
WHO global report on hypertension 2025..Farrar J, Frieden T. Lancet. 2025 Nov 15;406(10517):2318-2319. Lire
Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. GBD 2023 Chronic Kidney Disease Collaborators. Lancet. 2025 Nov 7:S0140-6736(25)01853-7. Lire
Role of Circadian Health in Cardiometabolic Health and Disease Risk: A Scientific Statement From the American Heart Association.Knutson KL, et al. Circulation. 2025 Oct 28. Lire
Revues
Renal Histology Findings in Malignant Hypertension, a Systematic Review. Maisons V, et al.Hypertension. 2025 Nov 4. Lire
Etudes de cohorte
Blood pressure variability is associated with heart failure risk, elevated NT-proBNP, and elevated high-sensitivity troponin: the Multi-Ethnic Study of Atherosclerosis (MESA). Nuyujukian DS, et al. Am J Hypertens. 2025 Nov 14:hpaf226. Lire
Hypertension in Young Adults: Social Determinants of Prevalence, Awareness, Treatment, and Control. Alexander TJ, et al. Am J Hypertens. 2025 Nov 13:hpaf203. Lire
Renal Denervation in Patients With Moderate to Severe Chronic Kidney Disease. Schlaich MP, et al. Hypertension. 2025 Oct 29. Lire
Post-Hoc de l’étude SPRINT
Relationship Between Home Blood Pressure Monitoring-Confirmed Resistant Hypertension and Cardiovascular Prognosis Kario K, et al. Hypertension. 2025 Oct 23. Lire
Effect of Intensive Systolic Blood Pressure Control on Markers of Cerebral Small Vessel Disease by Age.Pruzin JJ, et al. Hypertension. 2025 Oct 29. Lire
Essais cliniques
DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial.Juraschek SP, et al.JAMA. 2025 Nov 9:e2521112. Lire
Recherche Fondamentale
Identification and Characterization of Alamandine-(1-5), a New Component of the Renin-Angiotensin System. Santos RAS, et al. Circ Res. 2025 Nov 12. Lire
Efficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial.Lamti F, et al.J Hypertens. 2025 Nov 1;43(11):1878-1884. doi: 10.1097/HJH.0000000000004141 LIRE
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. Flack JM, Azizi M, et al; BaxHTN Investigators. N Engl J Med. 2025 Oct 9;393(14):1363- 1374. doi: 10.1056/NEJMoa2507109 LIRE
Revues
Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.Guo X, et al; BPRULE Study Group.Lancet. 2025 Sep 6;406(10507):1009-1019. doi: 10.1016/S0140-6736(25)01391-1. LIRE
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension. Krychtiuk KA, et al. Hypertension. 2025 Oct;82(10):1599-1611. doi: 10.1161/HYPERTENSIONAHA.125.24992. LIRE
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Romeo S, et al; European Atherosclerosis Society Consensus. Eur Heart J. 2025 Oct 7;46(38):3685-3713. doi:10.1093/eurheartj/ehaf314. LIRE
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Adler GK,et al. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284 LIRE
Post-hoc analyses of clinical trials
Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. Li S, et al; ESPRIT Investigators. J Am Coll Cardiol. 2025 Oct 15:S0735-1097(25)07783-6. doi: 10.1016/j.jacc.2025.08.092. LIRE
Systolic Blood Pressure Time in Target Range and Acute Kidney Injury in Patients With Hypertension. Chen WH, et al. Hypertension. 2025 Oct 9. doi: 10.1161/HYPERTENSIONAHA.125.25511. LIRE
Etudes observationnelles
Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort. Lau ES, et al. Circulation. 2025 Oct 14;152(15):1044-1055. doi: 10.1161/CIRCULATIONAHA.125.074692. LIRE
Shiny and Mobile Apps for Estimating Blood Pressure Percentiles in Children. Montelisciani L, et al. Hypertension. 2025 Oct 1. doi: 10.1161/HYPERTENSIONAHA.125.25087. LIRE
Prescription Trends of Hydrochlorothiazide vs. Chlorthalidone in the United States (2019-2024). Asante R, et al. Am J Hypertens. 2025 Sep 23:hpaf190. doi: 10.1093/ajh/hpaf190. LIRE
Poor Accuracy of Blood Pressure Measurement Images Online: Implications for Public Health Education. Aminde LN, et al. Hypertension. 2025 Sep 8. doi: 10.1161/HYPERTENSIONAHA.125.25064 LIRE
Association Between Migraine and Hypertension in 2 Million Adolescents. Akavian I, et al. Hypertension. 2025 Sep 4. doi: 10.1161/HYPERTENSIONAHA.125.24861. LIRE
La France à l’honneur: essai RETREAT-FRAIL Reduction of Antihypertensive Treatment in Nursing Home Residents. Benetos A, et al. Published on August 29, 2025, at NEJM.org. DOI: 10.1056/NEJMoa2508157. LIRE
Nouvelles recommandations US, AC/AHA dans l’HTA publiées conjointement dans Circulation et Hypertension 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Jones DW, et al. Circulation. 2025 Aug 14. doi: 10.1161/CIR.0000000000001356 LIRE
Nouvelle recommandation : 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy LIRE
Efficacy and Safety of Baxdrostat in uncontrolled and resistant hypertension. Flack JM et al. N Engl J Med 2025 Aug 30. doi: 10.1056/NEJMoa2507109. Online ahead of print LIRE
Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. Bitar YSL, et al. J Hypertens. 2025 Sep 1;43(9):1485-1491. doi: 10.1097/HJH.0000000000004075 LIRE
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Wang N, et al. Lancet. 2025 Aug 30;406(10506):915-925. doi: 10.1016/S01406736(25)00991-2 LIRE
Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study Goupil R, et al. Circulation. 2025 Jul 9:10.1161/CIRCULATIONAHA.124.073507. PMID: 40631720. LIRE
Long-term prediction of blood pressure reduction after renal denervation for arterial hypertension, Sagmeister P, at al. J Hypertens. 2025 Jul 7. PMID: 40621832 LIRE
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial, Saxena M, et al; Launch-HTN Investigators. JAMA. 2025 Jun 30:e259413. PMID: 40587141 LIRE
Adrenalectomy Versus Medical Therapy in Primary Aldosteronism: A Meta-Analysis of Long-Term Cardiac Remodeling and Function: Medical Versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) Study, Marzano L, et al. Hypertension. 2025 Jun 25. PMID: 40557482 LIRE
Sympathetic Overactivation in the Resistant Hypertensive Phenotype: A Meta-Analysis of Published Studies, Grassi G, et al. Hypertension. 2025 Jun 18;82(8):1346-54. PMID: 40528744 LIRE
Nocturnal blood pressure: pathophysiology, measurement and clinical implications. Position paper of the European Society of Hypertension, Parati G, et al; ESH Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2025 Aug 1;43(8):1296-1318. PMID: 40509714 LIRE
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.Laffin LJ, et al; Advance-HTN Investigators. N Engl J Med. 2025 May 8;392(18):1813-1823.Pour en savoir plus : Lire
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.Desai AS, et al; KARDIA-2 Study Group. JAMA. 2025 May 28:e256681. Pour en savoir plus : Lire
Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.He Y, et al. Circulation. 2025 May 27;151(21):1544-1546. Lire
Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. Lee CJ, et al. JAMA. 2025 May 14:e255129. Pour en savoir plus : Lire
Establishing Reference Values for Pulse Wave Velocity in Young People.Kodithuwakku V, et al; Youth Vascular Consortium collaborators. Hypertension. 2025 May 14. doi: 10.1161/HYPERTENSIONAHA. Pour en savoir plus: Lire
Heat extremes and cardiovascular Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy.Chaseling GK, et al. Eur Heart J. 2025 Jun 3:ehaf326. Pour en savoir plus Lire
Priorities for Research on Hypertension Care Delivery: A WHO Report Executive Summary. Matsushita K, et al. Hypertension. 2025 Jun;82(6):971-976. doi: 10.1161/HYPERTENSIONAHA.125.24702. PMID: 40109247 Pour en savoir plus : Lire
Leung AA, et al. Confirmatory Testing for Primary Aldosteronism : A Study of Diagnostic Test Accuracy. Ann Intern Med. 2025 May 6. Lire
Messerli FH, Ram CVS, Burnier M. Low-Salt Diet and Thiazide Diuretics. Circulation. 2025 May 6;151(18):1297-1298. doi: 10.1161/CIRCULATIONAHA.125.074388 Lire
Li C, et al. Effect of aerobic exercise on endothelial function in hypertensive and prehypertensive 43(5):727-738. doi: 10.1097/HJH.0000000000003980 Lire
Sahlin C, et al. Cardiovascular effects after five nights without continuous positive airway pressure for obstructive sleep 43(5):864-870. doi: 10.1097/HJH.0000000000003990 Lire
Vahtera V, et al. Incidence of new onset arterial hypertension after metabolic bariatric 43(5):871-879. doi: 10.1097/HJH.0000000000003993 Lire
Tamargo J, et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024. Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):292-317. doi: 10.1093/ehjcvp/pvaf012 Lire
Bonaca MP, et al; STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4 Lire
